Therefore, the differential binding of KLF14 and EGR2 and expression of downstream EPHA4 impact both tumor growth and drug sensitivity, suggesting that chromatin remodeling in different PDMC may interfere with their ability to predict therapeutic outcomes. This evidence concerns the gene EPHA4 and neoplasm.